Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 11/20 | 0.55 |
| ▸ | CES2 | O00748 | 11/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018336 | 0.83 | CES1 (0.56) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL8980055 | 0.81 | NAAA (0.60) | CES1CES2HPGDSMN1; SMN2NAAA | |
| SCHEMBL10966143 | 0.80 | CES1 (0.52) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL7178427 | 0.80 | GAA (0.44) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL8657972 | 0.79 | CES1 (0.52) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL11583619 | 0.79 | HDAC1 (0.53) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL7300892 | 0.79 | CES1 (0.52) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL28791135 | 0.79 | CES1 (0.52) | CES1CES2GAAHPGDMAPT | |
| SCHEMBL1109840 | 0.79 | CES1 (0.46) | CES1CES2GAAHPGDMAPT | |
| Benzil SCHEMBL28793382 | 0.78 | CES2 (0.64) | CES1CES2HPGDMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | claimed |
| CN-115093373-A | 1, 5-disubstituted-3-fluoroalkyl-1, 2, 4-triazole compound and preparation method and application thereof | 江苏省中国科学院植物研究所 | 2022-09-23 | — | — | CN | disclosed |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015175845-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-8232420-B2 | Asymmetric catalyst and process for preparing optically active alcohols using the same | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100261924-A1 | ASYMMETRIC CATALYST AND PROCESS FOR PREPARING OPTICALLY ACTIVE ALCOHOLS USING THE SAME | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100069683-A1 | Organic metal compound and process for preparing optically-active alcohols using the same | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090062573-A1 | Organic metal compound and process for preparing optically-active alcohols using the same | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2009-03-05 | — | — | US | disclosed |
| US-5763436-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5556998-A | Transition metal complex, process for the preparation of the same, and asymmetric hydrogenation catalyst comprising the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | ACSS2, GLS2, ACSL3 | CES1 106/4885CES2 281/4885GAA 747/4885 |
| US-20090062573-A1 | Organic metal compound and process for preparing optically-active alcohols using the same | ADH1C, ADH1A, ADH5 | CES1 706/4885CES2 1519/4885GAA 3049/4885 |
| US-20100261924-A1 | ASYMMETRIC CATALYST AND PROCESS FOR PREPARING OPTICALLY ACTIVE ALCOHOLS USING THE SAME | ADH1A, ADH1C, ADH5 | CES1 878/4885CES2 1247/4885GAA 4102/4885 |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | ACSS2, GLS2, ACSL3 | CES1 106/4885CES2 281/4885GAA 747/4885 |
| US-20100069683-A1 | Organic metal compound and process for preparing optically-active alcohols using the same | ADH1C, ADH1A, ADH5 | CES1 706/4885CES2 1519/4885GAA 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.